Electric pulses augment reporter gene expression in the beating heart

Journal of Gene Medicine

Volumn 14, Issue 3, 2012, Pages 191-203

  Eigeldinger Berthou, Sylvie ^a   Buntschu, Patrick ^a   Flück, Martin ^a,b   Frobert, Aurélien ^a   Ferrié, Céline ^a   Carrel, Thierry P ^a   Tevaearai, Hendrik T ^a   Kadner, Alexander ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Gene; Inflammation; Myocardium; Reporter; Somatic; Transfection

Indexed keywords

GREEN FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL INFILTRATION; ELECTRICITY; GENE EXPRESSION; HEART BEAT; HEART LEFT VENTRICLE; HEART MUSCLE CELL; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPORTER GENE; SOMATIC GENE THERAPY; SURVIVAL;

ANALYSIS OF VARIANCE; ANIMALS; ELECTROPORATION; GENE THERAPY; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; MALE; MYOCYTES, CARDIAC; PLASMIDS; RATS; RATS, INBRED LEW; TRANSFECTION;

RATTUS;

EID: 84858676493     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2603     Document Type: Article

References (40)

1. Melo LG, Pachori AS, Kong D, et al. Gene and cell-based therapies for heart disease. FASEB J 2004; 18: 648-663.
2. Villemejane J, Mir LM. Physical methods of nucleic acid transfer: general concepts and applications. Br J Pharmacol 2009; 157: 207-219.
3. Pathak A, Patnaik S, Gupta KC. Recent trends in non-viral vector-mediated gene delivery. Biotechnol J 2009; 4: 1559-1572.
4. Katz MG, Swain JD, White JD, et al. Cardiac gene therapy: optimization of gene delivery techniques in vivo. Hum Gene Ther 2010; 21: 371-380.
5. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171-181.
6. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000; 60: 249-271.
7. Njeim MT, Hajjar RJ. Gene therapy for heart failure. Arch Cardiovasc Dis 2010; 103: 477-485.
8. Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J 2009; 11: 671-681.
9. Wells DJ. Electroporation and ultrasound enhanced non-viral gene delivery in vitro and in vivo. Cell Biol Toxicol 2010; 26: 21-28.
10. Escoffre JM, Portet T, Wasungu L, et al. What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues. Mol Biotechnol 2009; 41: 286-295.
11. Gissel H. Effects of varying pulse parameters on ion homeostasis, cellular integrity, and force following electroporation of rat muscle in vivo. Am J Physiol Regul Integr Comp Physiol 2010; 298: R918-R929.
12. Durieux AC, Bonnefoy R, Manissolle C, et al. High-efficiency gene electrotransfer into skeletal muscle: description and physiological applicability of a new pulse generator. Biochem Biophys Res Commun 2002; 296: 443-450.
13. Andre F, Mir LM. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther 2004; 11(Suppl 1): S33-S42.
14. Hojman P, Gissel H, Andre FM, et al. Physiological effects of high- and low-voltage pulse combinations for gene electrotransfer in muscle. Hum Gene Ther 2008; 19: 1249-1260.
15. Davalos RV, Rubinsky B, Mir LM. Theoretical analysis of the thermal effects during in vivo tissue electroporation. Bioelectrochemistry 2003; 61: 99-107.
16. Mir LM, Bureau MF, Rangara R, et al. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. CR Acad Sci III 1998; 321: 893-899.
17. Graham RM, Bishopric NH, Webster KA. Gene and cell therapy for heart disease. IUBMB Life 2002; 54: 59-66.
18. Dosdall DJ, Fast VG, Ideker RE. Mechanisms of defibrillation. Annu Rev Biomed Eng 2010; 12: 233-258.
19. Marshall WG Jr, Boone BA, Burgos JD, et al. Electroporation-mediated delivery of a naked DNA plasmid expressing VEGF to the porcine heart enhances protein expression. Gene Ther 2010; 17: 419-423.
20. Ayuni EL, Gazdhar A, Giraud MN, et al. In vivo electroporation mediated gene delivery to the beating heart. PLoS One 2010; 5: E14467.
21. Durieux AC, D'Antona G, Desplanches D, et al. Focal adhesion kinase is a load-dependent governor of the slow contractile and oxidative muscle phenotype. J Physiol 2009; 587: 3703-3717.
22. Goldner J. A modification of the masson trichrome technique for routine laboratory purposes. Am J Pathol 1938; 14: 237-243.
23. Day S, Davis J, Westfall M, et al. Genetic engineering and therapy for inherited and acquired cardiomyopathies. Ann NY Acad Sci 2006; 1080: 437-450.
24. Holladay CA, O'Brien T, Pandit A. Non-viral gene therapy for myocardial engineering. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2: 232-248.
25. Dahl CF, Ewy GA, Warner ED, et al. Myocardial necrosis from direct current countershock. Effect of paddle electrode size and time interval between discharges. Circulation 1974; 50: 956-961.
26. Fedorov VV, Nikolski VP, Efimov IR. Effect of electroporation on cardiac electrophysiology. Methods Mol Biol 2008; 423: 433-448.
27. Wulfsohn D, Nyengaard JR, Tang Y. Postnatal growth of cardiomyocytes in the left ventricle of the rat. Anat Rec A Discov Mol Cell Evol Biol 2004; 277: 236-247.
28. Durieux AC, Bonnefoy R, Busso T, et al. In vivo gene electrotransfer into skeletal muscle: effects of plasmid DNA on the occurrence and extent of muscle damage. J Gene Med 2004; 6: 809-816.
29. Wooddell CI, Subbotin VM, Sebestyen MG, et al. Muscle damage after delivery of naked plasmid DNA into skeletal muscles is batch dependent. Hum Gene Ther 2011; 22: 225-235.
30. Fluck M, Mund SI, Schittny JC, et al. Mechano-regulated tenascin-C orchestrates muscle repair. Proc Natl Acad Sci USA 2008; 105: 13662-13667.
31. Kawase Y, Ly HQ, Prunier F, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008; 51: 1112-1119.
32. del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 2001; 104: 1424-1429.
33. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000; 97: 793-798.
34. Mou Y, Ye Y, Zhao XY, et al. Partial restoration of left ventricular systolic function by asPLB gene transfer using ultrasound-mediated microbubble destruction. Ultrasound Med Biol 2009; 35: 1638-1646.
35. Yoon YS, Uchida S, Masuo O, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005; 111: 2073-2085.
36. Reilly JP, Grise MA, Fortuin FD, et al. Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J Interv Cardiol 2005; 18: 27-31.
37. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105: 2012-2018.
38. von der Leyen HE, Mugge A, Hanefeld C, et al. A prospective, single-blind, multicenter, dose escalation study of intracoronary iNOS lipoplex (CAR-MP583) gene therapy for the prevention of restenosis in patients with de novo or restenotic coronary artery lesion (REGENT I extension). Hum Gene Ther 2011; 22: 951-958.
39. Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure. [4 March 2010].
40. Grossman PM, Mendelsohn F, Henry TD, et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007; 153: 874-880.